such as cytokines and adhesion molecules. Of these costimulatory signals, the CD28 antigen has attracted the greatest interest because the interaction of CD28 with its natural ligands (B7-1, B7-2, and B7-3) seems to be the most potent second signal for T-cell activation.' The physiologic T-cell stimulation by an APC can be substituted by cross-linking of MoAbs directed to the respective T-cell triggering molecules. By using a combination of two Bi-MoAbs that target with one arm a tumor-associated antigen and with the other the CD3 or CD28 antigen on T cells, respectively, an antigen-specific and MHC nonrestricted T-cell activation at the tumor site can be achieved.x~' I We have recently described the successful use of Bi-MoAbs with specificity for the CD3 and CD28 antigen on T lymphocytes and the Hodgkin's associated CD30 antigen to induce cytokine secretion and proliferation of human T cells in the presence of CD30C Hodgkin's-derived cells. Moreover, target cells expressing the CD30 antigen were lysed in an antibody and effector cell concentration-dependent fashion.' Treatment of severe combined immunodeficient (SCID) mice bearing established CD30' positive subcutaneous Hodgkin's tumors with a combination of these Bi-MoAbs followed by the application of human T cells that had been prestimulated in vitro by CD30' tumor cells in the presence of CD3/CD30 Bi-MoAb resulted in the complete cure of the animals from the xenografted tumors." As this approach represents the most effective immunotherapeutic model for the treatment of human neoplasms to date, we were interested to modify this model in a way that facilitates its applicability to the clinical situation. These modifications concerned the in vitro prestimulation of the human effector T cells and the sequence of application of Bi-MoAbs and human lymphocytes. Most importantly, however, we wanted to test this approach in a preclinical model of disseminated tumor growth and define the conditions under which this approach might be curative in advanced neoplastic disease. Our results demonstrate that by using a simplified treatment protocol with naive human T cells, disseminated xenografted
T cells, which in contrast to NK cells do not have cytolytic granula stored in their cytoplasm:.' mediate cytotoxicity only after appropriate activation. According to the current concept of T-cell activation, two antigenic stimuli are needed to activate resting human T cells adequately. 6 The interaction of the T cell with the antigen-presenting cell (APC) is usually characterized by the T-cell antigen receptor (TCR)-mediated recognition of major histocompatibility complex (MHC) restricted peptide presented by APC. This recognition results in T-cell activation and proliferation if an additional costimulatory signal is provided by soluble or cellular mediators, such as cytokines and adhesion molecules. Of these costimulatory signals, the CD28 antigen has attracted the greatest interest because the interaction of CD28 with its natural ligands (B7-1, B7-2, and B7-3) seems to be the most potent second signal for T-cell activation. ' The physiologic T-cell stimulation by an APC can be substituted by cross-linking of MoAbs directed to the respective T-cell triggering molecules. By using a combination of two Bi-MoAbs that target with one arm a tumor-associated antigen and with the other the CD3 or CD28 antigen on T cells, respectively, an antigen-specific and MHC nonrestricted T-cell activation at the tumor site can be achieved.x~' I We have recently described the successful use of Bi-MoAbs with specificity for the CD3 and CD28 antigen on T lymphocytes and the Hodgkin's associated CD30 antigen to induce cytokine secretion and proliferation of human T cells in the presence of CD30C Hodgkin's-derived cells. Moreover, target cells expressing the CD30 antigen were lysed in an antibody and effector cell concentration-dependent fashion.' Treatment of severe combined immunodeficient (SCID) mice bearing established CD30' positive subcutaneous Hodgkin's tumors with a combination of these Bi-MoAbs followed by the application of human T cells that had been prestimulated in vitro by CD30' tumor cells in the presence of CD3/CD30 Bi-MoAb resulted in the complete cure of the animals from the xenografted tumors." As this approach represents the most effective immunotherapeutic model for the treatment of human neoplasms to date, we were interested to modify this model in a way that facilitates its applicability to the clinical situation. These modifications concerned the in vitro prestimulation of the human effector T cells and the sequence of application of Bi-MoAbs and human lymphocytes. Most importantly, however, we wanted to test this approach in a preclinical model of disseminated tumor growth and define the conditions under which this approach might be curative in advanced neoplastic disease. Our results demonstrate that by using a simplified treatment protocol with naive human T cells, disseminated xenografted 
MATERIALS AND METHODS

Animals.
Four to six week-old pathogen-free mice with severe combined immunodeficiency (C.B-17 Icr scidscid) were obtained from the Institut fur Versuchstierzucht (Hannover, Germany). Animals were housed and bred in pathogen-free cages and fed with autoclaved standard chow and water. To eradicate residual NK cells, mice were treated on days -3,O. + 3 before and after the application of human lymphocytes with 100 pL anti-asialo GM-l antibody (Wako, Osaka, Japan) intraperitoneally (IP).
Cell lines and Bi-MoAbs. The CD30' human Hodgkin's-derived cell line L54OCY and the T-cell activating CD3/CD30 and CD28/ CD30 Bi-MoAbs used in this study have been described before.'.'' Establishment of disseminated Hodgkin's lymphoma in SCID mice. Except for titration experiments, 2 X IO' cells of the Hodgkin's-derived L54OCY cell line were injected into the ventral tail vein of SCID mice. To prevent pulmonary embolism caused by the injection of tumor cells, mice were anesthesized by ether inhalation, tumor cells were suspended in 400 pL sterile phosphate-buffered saline (PBS) + 0.1 % bovine serum albumin (BSA) and administered intravenously (IV) over a period of 10 seconds. Blood samples were taken every 3 days, and the level of sCD30 was determined by enzyme-linked immunosorbent assay (ELISA).'' For tumor cell titration experiments, animals were divided into groups of ten. All animals that showed signs of advanced tumor disease or that lived longer than 150 days were killed and examined for macroscopic signs of tumor growth. In addition, major organs were resected, examined macroscopically and microscopically and subjected to immunohistological and FACScan analysis as described.'' In addition, Northern blot analysis and reverse transcriptose-polymerase chain reaction (RT-PCR) was performed for human CD30 mRNA.
Prepurations of T cells. Peripheral blood mononuclear cells (PBMC) were isolated as de~cribed.~ After leucine-methyl-ester treatment (LME), T cells were negatively enriched by immunomagnetic depletion of CD14, CD16, CD19, and HLA-DR expressing cells using a VarioMACS system (Miltenyi, Bergisch Gladbach, Germany). Briefly, 1 X 10' lymphocytes were washed twice in cold MACS buffer (PBS + 1% BSA + 0.05% azide), the cell pellet was resuspended in 100 pL MACS buffer with MoAbs (IO pg) directed against the respective antigens, and the mixture was incubated at 4°C for 15 minutes. After two courses of washing with MACS buffer, goat antimouse immunoglobulin beads (30 pg/rnL) were added, and the mixture was incubated at 4°C for 15 minutes. The separation of unstained lymphocytes was performed following the manufacturer's recommendations. The remaining lymphocyte population was >95% CD3.' Contaminating cell populations were always <0.5%, and no proliferation after phorhol myristate acetate (PMA) stimulation (10 ng/mL) and phytohemagglutinin (PHA) (1 pg/mL) for 2 to 5 days in culture was observed. For in vivo studies with subsets of human T cells, negative peripheral blood lymphocytes were negatively enriched for T lymphocytes as described above and divided into CD4+ and CD8+ subsets by MACS. Punty of T-cell subset preparations used for 1V administration was checked by FACScan analysis and was always >98%.
Treatment of xenogrufted tumors in vivo. Animals bearing disseminated Hodgkin's tumors were divided into groups of five and subjected to different treatment protocols. The treatment started with the IV application of bispecific antibody (50 pg/mouse). This was followed by the IV administration of 2 X lo7 resting CD3' lymphocytes 48 hours later. In one series of experiments, CD8' and 0 4 ' T-cell subsets were injected instead of CD3' lymphocytes, and in another series the injection of the lymphocytes preceded the injection of both Bi-MoAbs or controls by 30 minutes, 1 hour, and 3 hours.
After treatment, animals were examined clinically and sCD30 levels were assayed every 3 days. Animals were killed after 150 days or when they showed signs of advanced disease. Survival was determined from the day of tumor inoculation until the day the animal was killed. Survival curves were plotted according to the method of Kaplan and Meier, and differences in survival between the treatment groups were determined by log rank test. All animals were examined for macroscopic and microscopic signs of tumor growth. In addition, major organs were resected and subjected to immunohistological and FACScan analysis, as well as Northern blot analysis and RT-PCR for human CD30 mRNA.
Depletion of human T lymphocytes in vivo. To deplete for CD8+ or CD4' T-cell subsets in vivo, each mouse received an IP injection of 100 pg mouse antihuman CD4 and antihuman CD8 antibody (IgG2a; Medac, Hamburg, Germany) or an irrelevant IgG2a control antibody, respectively, 72 hours and 120 hours after the application of CD3' lymphocytes.
Northern blot analysis. Total RNA was isolated from resected tissues by using guanidinium is~thiocyanate.'~ Samples of 20 pg RNA were fractionated on 1% formaldehyde agarose gels, then transferred and cross-linked to nitrocellulose. Blots were hybridized with "P-labeled probes by using a formamide buffer system (50% formamide, 5 X SSC, 5 X Denhardts, 1% SDS, and 200 pg/mL heat denaturated salmon sperm) at 42°C for 12 to 16 hours. After hybridization, membranes were washed two times at 42°C for 15 minutes and exposed to X-ray films for 24 to 48 hours. A CD30 antigen specifc cDNA fragment of 500 bp length covering a part of the coding region was generated by RT-PCR labeled by random priming (Pharmacia, Freiburg, Germany). A P-actin probe was used as control for equal RNA loading per lane.
RT-PCR. cDNA was generated using poly A-mRNA extracted from Hodgkin cell lines or different tissues resected from sacrificed SCID mice.I5 For the specific amplification of the CD30 antigen coding cDNA, a 5' primer (bp 521-544) and a 3' primer (bp 1054-1075) amplifying a 533-bp fragment were constructed. PCR was performed at 64°C for 32 cycles and amplified products fractionated on a 2% agarose gel containing ethidium-bromide for DNA staining. Soluble CD30 antigen as a parameter j b r tumor growth. To assure that only xenografted SCID mice with a successful tumor take and established tumors were treated with the immunotherapy protocol, a more prospective parameter than survival or histological examination of involved organs was needed. As shown in Fig 1, serum levels of soluble CD30 derived from the xenografted CD30' Hodgkin's cells proved to be a reliable marker for tumor growth. After IV injection of 2 X IO' cells, sCD30 levels became detectable 5 days after IV injection of 2 X lo7 tumor cells and peaked at day 35. All animals had to be killed on day 40 because of progressive tumor cachexia.
RESULTS
Establishment of disseminated
There was a good correlation between C D 3 0 levels and the degree of tumor infiltration in different organs of tumorbearing animals as determined by immunohistology, fluorescence-activated cell sorter (FACS) analysis of CD30' cells, and Northern blots for human CD30 mRNA from organs of animals killed at different time points after inoculation of tumor cells.
Prestiimulatiorr of human lymphocytes in vitro. In our original protocol, human lymphocytes were prestimulated in vitro for 72 hours with CD30+ Hodgkin's cells in the presence of Bi-MoAb CD3KD30. As this prestimulation in vitro would considerably complicate a clinical protocol, we tested its effect on the efficacy of the Bi-MoAb treatment in vivo. Treatment of tumor-bearing SCID mice with both naive and appropriately in vitro prestimulated human peripheral blood lymphocytes together with CD3/CD30 and CD28KD30 BiMoAbs resulted in 100% cure of mice from xenografted Hodgkin's tumors. This indicates that in vitro prestimulation with CD30' tumor cells in the presence of CD3/CD30 BiMoAb is not necessary for the induction of effective tumorilytic activity of human lymphocytes in vivo. Therefore, in all following experiments, prestimulation of human lymphocytes in vitro was abandoned.
Treatment of disseminated xenografted Hodgkin's tumors. 
Macroscopic and microscopic examination of the sacrificed animals showed diffuse tumor growth in the control animals, but no detectable tumor in the appropriately treated animals. That the latter group was indeed cured from their tumors was also suggested by the immunohistological and Northern blot analysis of lymph nodes, spleen, liver. bones, and lungs from these animals on day 150 which showed no detectable remaining CD30' cells or CD30-specific mRNA. respectively (Fig 3) . In addition, the more sensitive examination of the same organs by RT-PCR for a human CD30 fragment showed no detectable levels of mRNA in cured mice.
Treatment o f advanced diseuse. To determine the maximal extent of disease that can be influenced by Bi-MoAbmediated immunotherapy, treatment of SCID mice bearing disseminated xenografted Hodgkin's tumors was started at different time intervals after the inoculation of the L54OCY cells. All animals treated 7 days after tumor inoculation were cured from their tumors. The survival rates obtained with the immunotherapeutic treatment started after 1 I and 14 days was 60% and 20%, respectively. No cure, but significantly ( P < .01) prolonged survival compared with control animals was observed when treatment was delayed until 2 I days after the inoculation of tumor cells (Fig 4) . Immunohistological examination showed that the tumors of animals progressing after immunotherapy were all CD30 positive.
Sequence ofapplicution of Bi-MoADs and humun iytnphocytes. In the clinical situation Bi-MoAbs would encounter circulating lymphocytes on their way to the tumor site. The binding of the Bi-MoAbs to circulating lymphocytes could interfere with their tumor binding and T-cell activating capacities. To test this possibility, human lymphocytes were injected into tumor-bearing SCID mice 30 minutes. I . and 3 hours before the application of Bi-MoAbs. As shown in Fig 5, the sequence of the application of the combination of CD3/CD30 and CD28KD30 Bi-MoAbs and the human lymphocytes did not influence the efficacy of the treatment: all animals with established disseminated xenografted Hodgkin's tumors, treated with human lymphocytes and the conbination of CD3/CD30 and CD28/CS30 Bi-MoAbs were cured, no matter whether the antibodies were given 2 days before the human lymphocytes or whether the injection o f the lymphocytes preceded the application of the human lymFor personal use only. on September 24, 2017. by guest www.bloodjournal.org From phocytes by 30 minutes, I . or 3 hours, respectively. Again, all control animals showed progressive tumor growth and had to be killed by day 40. Thus, circulating human lymphocytes did not interfere with the efficacy of the Bi-MoAb therapy.
Role of Itlttnnn T-lynpltocp srrhsets on rrntitrtmor efects in 19i1~0. To evaluate the impact of different lymphocyte subsets on tumor cell lysis in vivo, two sets of experiments were performed. When purified resting CD4' or CD8' lymphocytes were injected with the Combination of CDYCD.30 and CD28/CD30 Bi-MoAbs (Fig 6A) . no effect of this treatment was observed when compared with control mice. Only the combination of both CD4' and CD8' lymphocytes resulted in the cure of tumor-bearing mice. suggesting that both subsets are crucial for efficient eradication of tumor cells.
To elucidate the question whether the combination of Different methods were used to evaluate treatment results in disseminated xenografted L540CY tumors in SCID mice: gross macroscopy, immunohistopathology, serum levels of soluble sCD30, and Northern blot analysis, as well as RT-PCR for human CD30 mRNA. All of these parameters showed a good degree of correlation. All animals with increasing sCD30 levels after therapy died of progressive tumors, while decreasing levels were associated with a successful treatment outcome (Fig 2) . Thus, similar to the situation in patients with Hodgkin's disease," sCD30 serum levels were simple and reliable monitors for tumor growth and were useful as early predictors for response to treatment. We also demonstrated in this study that application of the Bi-MoAbs after the human effector cells, ie, the IV injection of Bi-MoAbs into tumor-bearing SCID mice with circulating human T cells was as effective as the reverse sequence in curing animals from disseminated tumors with injections of the Bi-MoAb 30 minutes, 1 hour, and 3 hours after the lymphocytes, all resulting in a 100% cure rate. While it had been reported that human lymphocytes are removed from the peripheral blood of SClD mice as early as I hour after injection using fluorescence in situ hybridization,Ix other studies, including one by our group, have demonstrated the persistence (or recirculation) of a significant proportion of 'H-uridine-labeled human lymphocytes in the peripheral blood of the SCID mice as long as 48 hours after IV injection.I9 Irrespective of this controversy, there is no doubt that at least the Bi-MoAbs injected after 30 minutes must have encountered circulating human lymphocytes. This demonstrates that circulating T cells do not interfere with the eventual binding of the Bi-MoAbs to the tumor cells and suggests that the circulating lymphocytes in the peripheral blood o f For The demonstration of prolonged persistence of the BiMoAbs at the tumor site and lymphocyte distribution studies" in tumor-bearing SCID mice had already suggested that the combination of CD3 and CD28 binding Bi-MoAbs has the potential for in-situ activation of human T lymphocytes. In addition, we had shown by RT-PCR and Northern blot analysis from tumor tissues taken 6 days after the initiation of treatment that mRNA for activation antigens such as CD25 was upregulated, and proliferation markers (eg, Ki-
67) and cytokines (eg, IL-2, tumor necrosis factor [ m ] -p )
were strongly expressed by tumor infiltrating human lymphocytes in vivo after application of both CD3 and CD28 Bi-MoAbs." Finally, the observation made in this study that prestimulation of human effector lymphocytes in vitro with CD30+ tumor cells can be abandoned without loss of therapeutic efficacy also indicates that both signals that are necessary for efficient activation of cytotoxic T cells can be delivered to the human T cells at the tumor site by cross-linking via the combination of the CD3KD30 and CD28KD30 BiMoAbs. The fact that the injection of either unstimulated CD4+ and CD8+ human T cells resulted in the loss of therapeutic efficacy points to the necessity of both subpopulations for the activation of cytotoxic T cells in vivo. Finally, the results of our in vivo depletion studies of human T-cell subsets with anti-CD4 and anti-CD8, respectively, support the hypothesis that after the initial activation, which necessitates both CD4' and CD8+, the cytotoxicity in vivo is exerted by either CD4' and CD8+, with the CD8+ subset being the more potent effector cells (Fig 6) . This is in complete accordance with the situation in vitro, where both CD4' and CD8+ cells confer Bi-MoAb-mediated cytotoxicity in vitro after appropriate prestimulation.*' Like other experimental approaches to immunotherapy of malignant tumors, the efficacy of our approach using BiMoAbs and human T cells depended on the time during the course of the disease at which the immunotherapy protocol was started: while all animals were cured with the treatment started on day 7, there was only a limited effect (significantly prolonged survival, but no cure) when treatment was delayed until day 21. This suggests that the antitumor effects of BiMoAb-activated human T cells depend on the tumor load. Whether this is due to immunosuppressive effects exerted by the tumor cells or is caused by pharmacokinetic problems inherent to large tumor masses, such as compromised accessibility for monoclonal antibodies and effector cells, remains to be determined.
The antitumor effects of Bi-MoAbs and human T cells against disseminated human Hodgkin's-derived tumors are CD30 antigen-specific, but MHC-nonrestricted, as CD30-transfected Chinese hamster ovary (CH0)-cells (that lack human MHC molecules) are as efficiently lysed as CD30+ Hodgkin's-derived cells, while CH0 cells transfected with the vector without insert, are resistant to treatment with BiMoAbs and human T cells prestimulated in vitro with CD30' tumor cells in the presence of CD3KD30 Bi-MoAbs." The non-MHC-restriction might also explain, to some degree, the high efficacy of the Bi-MoAb approach: while the requirement for a specific TCFUMHC interaction limits considerably the number of T cells that can be induced to exert a cytotoxic function, Bi-MoAbs with the indicated properties can confer anti-CD30 antigen-directed specificity to a majority of resting T cells. To another part, the success of this model may also be due to the reciprocal expression of adhesion molecules by the Hodgkin's-derived tumor cell lines For personal use only. on September 24, 2017. by guest www.bloodjournal.org From (which in this regard closely resemble H&RS cells in vivo) and human T cells. This is suggested by the observation that blocking of the leukocyte function antigen-l (LFA-I)/ intercellular adhesion molecule-1 (ICAM-1) or CD2LFA-3 adhesion pathway with the respective MoAbs decreases BiMoAb-mediated T-cell cytotoxicity in this model.*' Therefore, the Bi-MoAb-mediated induction of T-cell cytotoxicity against tumors can be expected to be most efficient in neoplastic cells that, in addition to a tumor-associated antigen that serves as a target for a T-cell activating Bi-MoAb, display the respective costimulatory adhesion molecules on their surface. Before all others, this holds true for tumors of hematopoietic origin, such as leukemias, lymphomas, and Hodgkin's disease. Finally, the demonstration that human T cells derived from patients with untreated Hodgkin's disease are as effective in this model as T lymphocytes from healthy controls does not only encourage the clinical evaluation of this approach in patients with refractory Hodgkin's disease, but also suggests that the T-cell deficiency described in Hodgkin's disease" affects mechanisms that are not relevant for the delivery of Bi-MoAb-mediated cytotoxicity or is compensated for by the combined cross-linking of CD3 and CD28 by the Bi-MoAbs via the H&RS cells. This is comparable to our findings of NK cell deficiencies in the same patients: while the NK cells from untreated Hodgkin's patients had a pronounced defect in classical NK cell activity (ie, cytotoxicity against the K562 cell line) when compared with normal controls, the CD16/CD30 Bi-MoAb-mediated NK cell cytotoxicity against L54OCY of these patients was as effective as that of normal controls against H&RS cells in vitro. Of course, one has to be cautious to draw conclusions from our in vivo SCID mouse data to the clinical situation, because normal immunity cannot be restored with human peripheral blood lymphocytes in the SCID mouse'x; however, that the in vitro findings have bearing on the clinical situation is suggested by early results of our ongoing trial with the NK-cell activating CD16KD30 Bi-MoAb in patients with refractory Hodgkin's disease, where we have observed clinical responses at doses as low as 4 mg/m' per patient.
In summary, we have established a preclinical model of a novel immunotherapeutic approach for the treatment of xenografted human tumors using Bi-MoAbs and human T cells. We have demonstrated that this approach is simple, does not depend on expensive and time-consuming in vitro stimulation procedures of human effector cells, and results in a high cure rate of disseminated tumors. We have investigated the role of T-cell subsets and could demonstrate that T cells derived from patients with active Hodgkin's disease are as effective as lymphocytes from healthy controls in this model. As the parental HRS-3 antibody has been shown to bind specifically to Hodgkin and Reed-Stemberg cell in patients with Hodgkin's disease,23 this approach should now be readily applicable to the clinical situation. As the NK cell activating CDI6KD30 Bi-MoAb, which was much less efficient in vitro and in the SCID mouse model than the combined CD3 + CD28 Bi-MoAb model, has shown encouraging activity in our ongoing phase MI trial in patients refractory to standard treatment (manuscript in preparation), there is reason to expect that the T-cell activating approach with the combination of CD3 and CD28 Bi-MoAb will become a major step forward in the conquest of Hodgkin's disease."
